Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 2
2024 6
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen YB, Nakamura R, Levine JE, Ferrara JLM. Akahoshi Y, et al. Among authors: eng g. Blood. 2024 Aug 29;144(9):1010-1021. doi: 10.1182/blood.2024025106. Blood. 2024. PMID: 38968143
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara JLM, Levine JE, Nakamura R. Akahoshi Y, et al. Among authors: eng g. Blood Adv. 2024 Apr 23;8(8):2047-2057. doi: 10.1182/bloodadvances.2023012091. Blood Adv. 2024. PMID: 38324721 Free PMC article.
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Al Malki MM, London K, Baez J, Akahoshi Y, Hogan WJ, Etra A, Choe H, Hexner E, Langston A, Abhyankar S, Ponce DM, DeFilipp Z, Kitko CL, Adekola K, Reshef R, Ayuk F, Capellini A, Chanswangphuwana C, Eder M, Eng G, Gandhi I, Grupp S, Gleich S, Holler E, Javorniczky NR, Kasikis S, Kowalyk S, Morales G, Özbek U, Rösler W, Spyrou N, Yanik G, Young R, Chen YB, Nakamura R, Ferrara JLM, Levine JE. Al Malki MM, et al. Among authors: eng g. Blood Adv. 2023 Sep 12;7(17):5189-5198. doi: 10.1182/bloodadvances.2023009853. Blood Adv. 2023. PMID: 37235690 Free PMC article. Clinical Trial.
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.
DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk F, Choe H, Etra A, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E, Ferrara JLM, Nakamura R, Levine JE, Chen YB. DeFilipp Z, et al. Among authors: eng g. Blood Adv. 2024 Jul 9;8(13):3488-3496. doi: 10.1182/bloodadvances.2024012561. Blood Adv. 2024. PMID: 38640197 Free PMC article.
A Day 14 Endpoint for Acute GVHD Clinical Trials.
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki MM, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp SA, Hexner E, Hoepting M, Hogan WJ, Kasikis S, Katsivelos N, Khan A, Kitko CL, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen YB, Nakamura R, Levine JE, Ferrara JLM. Spyrou N, et al. Among authors: eng g. Transplant Cell Ther. 2024 Apr;30(4):421-432. doi: 10.1016/j.jtct.2024.01.079. Epub 2024 Feb 4. Transplant Cell Ther. 2024. PMID: 38320730 Free PMC article.
The utility of biomarkers in acute GVHD prognostication.
Spyrou N, Akahoshi Y, Ayuk F, Holler E, Choe H, Etra A, Hogan WJ, Rösler W, Hexner E, DeFilipp Z, Reshef R, Chanswangphuwana C, Qayed M, Kraus S, Eder M, Javorniczky NR, Grupp SA, Kitko CL, Merli P, Aguayo-Hiraldo P, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Khan A, Kowalyk S, Morales G, Young R, Nakamura R, Chen YB, Levine JE, Ferrara JLM. Spyrou N, et al. Among authors: eng g. Blood Adv. 2023 Sep 12;7(17):5152-5155. doi: 10.1182/bloodadvances.2023009929. Blood Adv. 2023. PMID: 37142257 Free PMC article. No abstract available.
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.
Rios CAO, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, Aguayo-Hiraldo P, Merli P, Hogan WJ, Weber D, Kitko CL, Ayuk F, Eder M, Grupp SA, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis IE, Morales G, Spyrou N, Young R, Nakamura R, Levine JE, Ferrara JLM, Akahoshi Y. Rios CAO, et al. Among authors: eng g. Transplant Cell Ther. 2024 Nov;30(11):1061.e1-1061.e10. doi: 10.1016/j.jtct.2024.08.019. Epub 2024 Sep 1. Transplant Cell Ther. 2024. PMID: 39222793
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, Hogan W, DeFilipp Z, Qayed M, Etra AM, Sandhu K, Kraus S, Olson T, Hexner E, Aguayo-Hiraldo P, Reshef R, Ullrich E, Schechter T, Kitko C, Chanswangphuwana C, Merli P, Akahoshi Y, Baez J, Eng G, Beheshti R, Kowalyk S, Morales G, Louloudis IE, Young R, Holler E, Nakamura R, Ferrara JLM, Levine JE. Katsivelos N, et al. Among authors: eng g. Transplant Cell Ther. 2025 Jan;31(1):10.e1-10.e9. doi: 10.1016/j.jtct.2024.10.012. Epub 2024 Dec 11. Transplant Cell Ther. 2025. PMID: 39667999